Is Sunrest Lifescie overvalued or undervalued?

As of 4 July 2025, the valuation grade for Sunrest Lifescie has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently considered fairly valued. Key ratios include a PE ratio of 11.16, an EV to EBITDA of 9.39, and a ROCE of 14.51%.
In comparison to peers, Sunrest Lifescie stands out against Elitecon International and Lloyds Enterprises, both categorized as very expensive with PE ratios of 176.28 and 202.81, respectively. This suggests that Sunrest Lifescie offers a more attractive valuation within the healthcare services sector. Notably, while the stock has underperformed over the past year with a return of -16.87% compared to the Sensex's 4.77%, its current valuation metrics indicate it is positioned well relative to its peers.